Multicenter, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Determine the Safety and Efficacy of Daclizumab HYP (DAC HYP) as a Monotherapy Treatment in Subjects With Relapsing-Remitting Multiple Sclerosis

Trial Profile

Multicenter, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Determine the Safety and Efficacy of Daclizumab HYP (DAC HYP) as a Monotherapy Treatment in Subjects With Relapsing-Remitting Multiple Sclerosis

Completed
Phase of Trial: Phase II

Latest Information Update: 22 Jun 2017

At a glance

  • Drugs Daclizumab (Primary)
  • Indications Multiple sclerosis
  • Focus Therapeutic Use
  • Acronyms SELECT
  • Sponsors Biogen Idec
  • Most Recent Events

    • 28 Apr 2017 Results examining degree of return of disease activity in patients with relapsing-remitting multiple sclerosis (RRMS) following discontinuation of treatment with daclizumab HYP (daclizumab) in SELECT/SELECTION Studies presented at the 69th Annual Meeting of the American Academy of Neurology
    • 09 Dec 2016 According to a Biogen media release, based on the results of this and other trial (DECIDE) Health Canada has approved ZINBRYTA™ (daclizumab beta), a new once-monthly, self-administered, subcutaneous treatment for adult patients with active relapsing remitting multiple sclerosis (RRMS).
    • 05 Jul 2016 According to Biogen media release, the European Commission (EC) approved ZINBRYTA™ (daclizumab), for the treatment relapsing forms of multiple sclerosis (RMS) in adult patients. The European Commission (EC) approval was based upon this and DECIDE trial.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top